Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
67.06 USD | -0.04% | -0.19% | +7.67% |
May. 16 | Axonics Implant Approved in Australia to Treat Overactive Bladders | MT |
May. 16 | Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.67% | 3.42B | |
+13.20% | 130B | |
-8.56% | 10.99B | |
-4.33% | 8.35B | |
+41.89% | 5.67B | |
-23.62% | 4.72B | |
-10.42% | 2.76B | |
-13.58% | 1.92B | |
-27.77% | 1.68B | |
-8.45% | 1.15B |
- Stock Market
- Equities
- AXNX Stock
- News Axonics, Inc.
- Transcript : Axonics, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 10